Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
13.10
-1.40 (-9.66%)
At close: Dec 5, 2025, 4:00 PM EST
11.00
-2.10 (-16.03%)
After-hours: Dec 5, 2025, 7:59 PM EST
Polyrizon Employees
As of December 31, 2024, Polyrizon had 6 total employees, including 2 full-time and 4 part-time employees.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$193,000
Market Cap
25.86M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLRZ News
- 2 days ago - From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection - GlobeNewsWire
- 3 days ago - Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product - GlobeNewsWire
- 4 days ago - Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform - GlobeNewsWire
- 4 weeks ago - Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation - GlobeNewsWire
- 2 months ago - Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy - GlobeNewsWire
- 2 months ago - Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker - GlobeNewsWire
- 3 months ago - Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study - GlobeNewsWire
- 4 months ago - Polyrizon Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire